Amgen

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Retrieved on: 
Tuesday, February 13, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Eli Lilly, Rutgers School of Engineering, CPA, Precision BioSciences, Gene editing, Marketing, Amgen, Precision, Hematology, Biomedical engineering, AbbVie, Management

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations to enhance and expand its IR program and communications with shareholders.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations to enhance and expand its IR program and communications with shareholders.
  • “Since joining Precision BioSciences as my Chief of Staff at the start of 2022, Naresh has had a unique vantage point to Precision’s management team and board of directors with a key role in executing our day-to-day operations and strategy,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences.
  • “Naresh’s breadth of experience before Precision, along with the deep knowledge gained since joining the company, position him to successfully lead communications with our shareholders.
  • Mr. Tanna joined Precision BioSciences in January 2022 as Chief of Staff to the CEO.

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Retrieved on: 
Monday, February 12, 2024
SAN, Connect, Investment, Marketing, Amgen, Atopic dermatitis, Johnson & Johnson, Asthma, Bristol Myers Squibb, Eos, CNTB, University, Therapy, Business, Patient, KPCB, GSK plc, Chemical engineering, Kleiner Perkins, Pharmaceutical industry

James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company.

Key Points: 
  • James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company.
  • “We are thrilled to welcome James to Connect’s Board of Directors,” said Wubin (Bill) Pan, Ph.D., M.B.A., Co-Founder, President, and Chairman of the Board of Connect Biopharma.
  • “His breadth of biotech and investment experience, coupled with his passion for innovative and transformative life science companies will provide our Board with a unique perspective.
  • Additionally, Mr. Huang serves as a director on the board of directors of a number of companies, including Kindstar Global, TacTiva Therapeutics, TriArm Therapeutics, Chime Biologics, Eos, GT Aperion, Domain, Asia Pacific Medical and XWPharma.

Green Technology & Sustainability Market worth $134.9 billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 12, 2024
Schneider Electric, Fujitsu, Sustainability, Investment, Amgen, Internet of things, IBM, Growth, DDEX, ESG, Social responsibility, Carbon, Climate, Accenture, GE HealthCare, Sustainable Development Goals, Organization, Cloud computing, Salesforce, Recycling, Microsoft, Environment, Partnership, Renewable energy

Businesses are adopting green technology & sustainability solutions to mitigate environmental impacts, comply with regulations, and adapt to changing market demands.

Key Points: 
  • Businesses are adopting green technology & sustainability solutions to mitigate environmental impacts, comply with regulations, and adapt to changing market demands.
  • Managed services are significantly impacting the Green Technology & Sustainability Market by providing businesses with outsourced, expert management of their IT infrastructure and services.
  • In the Asia Pacific region, the adoption of green technology & sustainability is on the rise, driven by several key factors.
  • Green Technology & Sustainability Market Advantages:
    Utility expenses can be lowered over time by reducing energy use with the use of various green technologies, like solar panels and energy-efficient appliances.

Green Technology & Sustainability Market worth $134.9 billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 12, 2024
Schneider Electric, Fujitsu, Sustainability, Investment, Amgen, Internet of things, IBM, Growth, DDEX, ESG, Social responsibility, Carbon, Climate, Accenture, GE HealthCare, Sustainable Development Goals, Organization, Cloud computing, Salesforce, Recycling, Microsoft, Environment, Partnership, Renewable energy

Businesses are adopting green technology & sustainability solutions to mitigate environmental impacts, comply with regulations, and adapt to changing market demands.

Key Points: 
  • Businesses are adopting green technology & sustainability solutions to mitigate environmental impacts, comply with regulations, and adapt to changing market demands.
  • Managed services are significantly impacting the Green Technology & Sustainability Market by providing businesses with outsourced, expert management of their IT infrastructure and services.
  • In the Asia Pacific region, the adoption of green technology & sustainability is on the rise, driven by several key factors.
  • Green Technology & Sustainability Market Advantages:
    Utility expenses can be lowered over time by reducing energy use with the use of various green technologies, like solar panels and energy-efficient appliances.

Biologic Therapeutic Drugs: Technologies and Global Market Report 2024, with Company Profiles of Amgen, Abbive, Eli Lilly, Novartis and Glaxosmithkline - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Health, Pharmaceutical, Eli Lilly, Amgen, ESG, Geography, Vaccine, Patent, Medicine, Novartis, Environment, Cancer, Pharmaceutical industry

The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The report also covers market projections through 2028, as well as key market players.
  • Estimate of the actual market size and revenue forecast, and a corresponding market share analysis by product type, therapeutic area and region.
  • Company profiles of major players within the industry, including Amgen, Abbive, Eli Lilly, Novartis and Glaxosmithkline

Lauren Barnes Joins Ossium Health’s Board of Directors

Retrieved on: 
Monday, February 12, 2024
Oncology, Health, Infectious Diseases, Stem Cells, Pharmaceutical, Biotechnology, Bone marrow, Senior, Commercialization, Amgen, Growth, Drug design, Access, Safety, Vertex Pharmaceuticals, Patient, Lauren Barnes, Avalere Health, Cancer Support Community

Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow banking platform, today announced the appointment of Lauren Barnes to its Board of Directors.

Key Points: 
  • Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow banking platform, today announced the appointment of Lauren Barnes to its Board of Directors.
  • “Lauren’s expertise and proven track record in biopharmaceutical commercialization are invaluable assets,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President.
  • In addition, Barnes serves as a board member for Ascelia Pharma AB, a Swedish oncology drug development company with two late-stage drug candidates, and she recently completed her time as Chair of the Board of Directors for the non-profit Cancer Support Community.
  • “I am incredibly excited to join Ossium’s Board of Directors at this pivotal moment in the company’s journey,” said Barnes.

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Standard of care, Immunotherapy, Amgen, Prostate cancer, Research, SITC, Society, Patient, ESSA, FDA, Publication, Biomarker, Doctor of Philosophy, NanoString Technologies, Therapy, Drug development, Biogen, Journal, University, Puma Biotechnology

Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.

Key Points: 
  • Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
  • “Zymeworks is honored to welcome Dr. Cesano to our board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • She joins three other new directors appointed in 2023: Mr. Derek Miller, Mr. Carlos Campoy, and Dr. Nancy Davidson.”
    “The Zymeworks board of directors is sincerely grateful to Dr. Hillan for his dedicated service and significant contributions to the board.
  • Dr. Cesano was also appointed to serve as a member of the research and development committee and nominating and corporate governance committee of the board of directors.

NSBE BOSTON'S INSPIRE STEM GALA PRESENTED BY AMGEN FEATURING JANEEN UZZELL AS KEYNOTE SPEAKER

Retrieved on: 
Wednesday, February 7, 2024
NSBE, Science, STEM, Process, Biotechnology, Diversity, United, Global health, United Nations, Social justice, National Society, Education, Associate, Amgen, Student, Management

The gala, themed "Black is STEM" this year, is NSBE Boston's annual fundraiser to support its mission of providing Youth STEM education and career programs for Black students in the Boston area.

Key Points: 
  • The gala, themed "Black is STEM" this year, is NSBE Boston's annual fundraiser to support its mission of providing Youth STEM education and career programs for Black students in the Boston area.
  • Since the first gala, NSBE Boston has awarded nearly $300,000 in scholarships and plans to award another $100,000 this year.
  • The event is presented by Amgen , a biotechnology leader that supports NSBE's vision of a more diverse and inclusive STEM future.
  • The gala will host over 200 business and community leaders to celebrate the outstanding Black STEM professionals and students in the region.

LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veterans Henry A. McKinnell, Ph.D., Anthony Gibney, and Francisco Leon, MD, Ph.D.

Retrieved on: 
Wednesday, February 7, 2024
Biotechnology, Growth, Yale University, Alexion, SVB Securities, Immune system, MD, Patient, Astellas Pharma, Merrill (company), FDA, MBA, Doctor of Philosophy, Pfizer, University, Business Roundtable, Food, Commerce, Therapy, Science, McKinnell, Senior advisor, Medical device, Business, Amgen, Connecticut Science Center, Pharmacy, Organization, Management

He is a member of the boards of directors of Nexcella and the Science and Technology in Society Forum.

Key Points: 
  • He is a member of the boards of directors of Nexcella and the Science and Technology in Society Forum.
  • His dual expertise in finance and biotech uniquely positions his insights at the intersections of financial strategy and operational expertise.
  • Joining the Board as a Board Observer, Dr. Leon will lend his significant expertise in clinical immunology, translational medicine and as a successful drug developer.
  • "I am honored to welcome new colleagues to the board,” added Dr. Fathallah.

Cartography Biosciences Expands Leadership Team with Appointment of Dan Rock, Ph.D., as Chief Scientific Officer to Advance Novel Oncology Programs into Clinic

Retrieved on: 
Wednesday, February 7, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Washington State University, Neoplasm, Knowledge, Metabolism, Therapy, Safety, Patient, CB21, Publication, Drug discovery, Spacecraft, University, University of Northern Colorado, Amgen, Pharmaceutical industry

Cartography Biosciences , an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Dan Rock, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Cartography Biosciences , an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Dan Rock, Ph.D., as Chief Scientific Officer.
  • In this role, Dr. Rock will be responsible for guiding the company’s scientific strategy and leading efforts to advance Cartography’s internal programs into the clinic.
  • “As Cartography moves into the next phase of development focused on advancing our internal pipeline discovered from our Atlas platform, we are thrilled to welcome Dan to the team.
  • “I’m honored to be joining a team at the forefront of innovation and I look forward to leading the team as Chief Scientific Officer in the pursuit of better treatment options for patients with cancer.”